Table 12.
Immunohistochemistry for PD-L1 in clinical studies.
| PD-L1 antibody | Cutoff for positivity of PD-L1 expression in tumor cell membrane | Percentage of tumor samples expressing PD-L1 | Study reference |
|---|---|---|---|
| 28-8 | 5% | 49% | Grosso et al., JCO, 2013 [37] |
| R&D B7-H1 | NR | 52% | Gatalica et al., CEBP, 2014 [38] |
| MIH1 | >10% | 50% | Konishi et al., CCR, 2004 [39] |
| 5H1 | >1% versus >5% versus high score | 21% (only CEC) | Marti et al., CCR, 2014 [30] |
| SP142 | 5% | 60% | |
| NR | 1% | 50% | Sun et al., JCO, 2014 [40] |
| 22C3 | ≥50% | 25% | Garon et al., NEJM, 2015 [27] |
| 28-8 | ≥1%, ≥5%, ≥10% | 53%, 36%, 25% (only CEC) | Brahmer et al., NEJM, 2015 [33] |
| SP142 | ≥1%, ≥5%, ≥10% | 68%, 37%, 16% | |
| SP142 | ≥1%, ≥5%, ≥10% | 56%, 28%, 13% | Herbst et al., Nature, 2014 [41] |